pyrroles has been researched along with Duncan Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Noguchi, K | 1 |
| Budde, K; Busque, S; Chan, G; Lamba, M; Lawendy, N; O'Connell, PJ; Russ, G; Silva, HT; Tortorici, MA; Vincenti, F; Wang, W; Yoshida, A | 1 |
1 review(s) available for pyrroles and Duncan Disease
| Article | Year |
|---|---|
[Epstein-Barr Virus Genome Replication as a Molecular Target for Cancer Therapy].
Topics: B-Lymphocytes; Burkitt Lymphoma; DNA Replication; Epstein-Barr Virus Nuclear Antigens; Genome, Viral; Herpesvirus 4, Human; Hodgkin Disease; Humans; Imidazoles; Lymphoproliferative Disorders; Molecular Targeted Therapy; Plasmids; Pyrroles; Replication Origin | 2019 |
1 other study(ies) available for pyrroles and Duncan Disease
| Article | Year |
|---|---|
Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients.
Topics: Adult; Biopsy; Cyclosporine; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Graft Rejection; Humans; Immunosuppressive Agents; Kidney; Kidney Transplantation; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors | 2015 |